$SENS News
Last published 1d ago
- 1d agoSENSSTIFEL 2026 HEALTHCARE CONFERENCE - SENSEONICS HOLDINGS INCEarnings Call TranscriptsThanks, guys. We're going to get started. Good afternoon. John Block with Stiefel, and I'm happy to welcome back the team from Senseonics. We have Tim Goodnow, CEO, Rick Sullivan, CFO, and Brian Hanson, CCO. These guys p
- 1d agoZETASENSTTWOSECZ+1Earnings Gaps Meet the Moving Averages on a Softer Morning for StocksPR NewswireStock Preachers News Commentary - The Bureau of Labor Statistics reported Tuesday morning that the Consumer Price Index for All Urban Consumers...
- 2d agoSENSSenseonics Third Quarter 2026 Earnings Call - SENSEONICS HOLDINGS INCEarnings Call TranscriptsGood day, everyone, and welcome to Senseonics' 3rd Quarter 2026 Earnings Call. At this time, all participants are in a listen-only mode. Later, you will have the opportunity to ask questions during the question-and-answe
- 2d agoSENSSenseonics Holdings, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 2d agoSENSSenseonics Holdings, Inc. Reports Third Quarter 2026 Financial ResultsGlobeNewswireGenerated third quarter revenue of $19.6 million, an increase of approximately 140% year-over-yearRaised full-year 2026 revenue guidance to $68 million to $70 million from $62 million to $66 million, representing
- 2w agoSENSSenseonics Initiates First-in-Human Study of Freedom, Designed to be the World’s First CGM System with No On-body ComponentGlobeNewswireFirst clinical evaluation of investigational, transmitter-free one-year CGM marks an important milestone on Senseonics’ innovation roadmap, with potential launch in 2028 Built on the proven sensing technology behind
- 2w agoSENSSenseonics Holdings, Inc. to Participate in Upcoming Investor ConferencesGlobeNewswireGERMANTOWN, Md., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ:SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose
- 3w agoSENSSenseonics Holdings, Inc. Schedules Third Quarter 2026 Earnings Release and Conference Call for November 9, 2026 at 4:30 P.M. Eastern TimeGlobeNewswireGERMANTOWN, Md., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ:SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose
- 1mo agoSENSBBNXSenseonics Announces Strategic Partnership with Beta Bionics to Integrate Eversense® 365 with the iLet® Bionic PancreasGlobeNewswirePairing year-long continuous glucose monitoring with automated insulin delivery to further simplify diabetes management for patients Brings Eversense 365 to the growing community of iLet Bionic Pancreas users Plan for
- 2mo agoSENSSenseonics To Participate in Upcoming Institutional Investor ConferencesGlobeNewswireGERMANTOWN, Md., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ:SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose
- 3mo agoSENSSenseonics Holdings, Inc. Reports Second Quarter 2026 Financial ResultsGlobeNewswireGenerated second quarter revenue of $14.5 million, an increase of approximately 120% year-over-yearRaising full-year 2026 revenue guidance to $62 million to $66 million from $60 million to $64 million, representing
- 3mo agoSENSSenseonics Holdings, Inc. Schedules Second Quarter 2026 Earnings Release and Conference Call for August 6, 2026 at 4:30 P.M. Eastern TimeGlobeNewswireGERMANTOWN, Md., July 21, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ:SENS) a medical technology company focused on implantable Continuous Glucose Monitoring (CGM) Systems for people with diabetes,
- 5mo agoSENSSenseonics and Welldoc Partner to Develop Next-Generation App for Eversense® 365GlobeNewswireThe new app will offer an enhanced user experience and exciting new features, including improved integration popular digital health tools The app is expected to launch in the second half of 2026 GERMANTOWN, Md. and
- 5mo agoSENSReal-World Evidence of Eversense 365 Presented at ADA Demonstrating Strong Performance and Patient Impact in Both Open and Closed Loop SystemsGlobeNewswireEversense 365 delivered favorable glucometrics compared to other open and closed loop systems, validating the one-year CGM's differentiated approach and high performance New data expands on findings shared at ATTD and
- 5mo agoSENSSenseonics Highlights Analyst Event and Oral Presentation of Eversense 365 Real-World Evidence at ADA 2026GlobeNewswireGERMANTOWN, Md., June 01, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ:SENS), a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable
- 6mo agoSENSSenseonics Holdings, Inc. Reports First Quarter 2026 Financial ResultsGlobeNewswireGenerated Q1 revenue of $11.7 million, an increase of 87% year-over-year Expect full-year revenue in the range of $60M - $64M (previously $58M to $62M) Strong strategic and commercial progress, including the launch of
- 6mo agoSENSSenseonics Announces Closing of $92 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional SharesGlobeNewswireGERMANTOWN, Md., May 04, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ:SENS), a medical technology company focused on the design, development and commercialization of long-term, implantable continuous
- 6mo agoHTGCSENSSenseonics Enters Into Amended Loan Agreement with Hercules to Increase Borrowing Capacity to $140 MillionGlobeNewswireGERMANTOWN, Md., May 04, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ:SENS) a medical technology company focused on the design, development and commercialization of glucose monitoring products designed to
- 6mo agoSENSSenseonics Holdings, Inc. Schedules First Quarter 2026 Earnings Release and Conference Call for May 7, 2026 at 4:30 P.M. Eastern TimeGlobeNewswireGERMANTOWN, Md., May 01, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ:SENS) a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable
- 6mo agoSENSSenseonics Announces Pricing of $80 Million Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewswireGERMANTOWN, Md., April 30, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ:SENS), a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable
- 6mo agoSENSSenseonics Announces Commencement of $80 Million Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewswireGERMANTOWN, Md., April 30, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ:SENS), a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable
- 6mo agoSENSTMDXTXGThe Quiet Rule Change Tilting $10B Toward Medtech's Most Validated PlatformsPR NewswireEquity-Insider.com News Commentary – Here's the quiet shift in medtech right now: the global medical imaging market is on track to grow from $41.64...
- 6mo agoSENSSenseonics Announces European Launch of Eversense® 365, The World's First and Only One Year CGM SystemGlobeNewswireThe next-generation CGM is now available in Sweden, with launches expected in Germany, Spain and Italy during the coming weeks as part of a phased roll out Eversense 365 doubles sensor lifespan from the previously
- 7mo agoSENSMBOTLIVNCLOVMedTech's Edge: How AI and Remote Diagnostics Drive Scalable ValuePR NewswireEquity-Insider.com News Commentary – The traditional hospital model is undergoing a massive structural shift. Outpatient clinics and ambulatory...
- 8mo agoSENSFirst Ever Real-World Evidence of Eversense 365 Presented at ATTD Demonstrates Sustained Performance and Positive Impact Throughout One-Year of WearGlobeNewswireNew data shows positive real-world impact of the world's first and only one-year CGM, with a full year of strong patient adherence, glucometrics and hypoglycemic outcomes Eversense 365 delivered comparable adherence and
- 8mo agoSENSSenseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2025 Financial ResultsGlobeNewswireGenerated Q4 revenue of $14.3 million, an increase of 72% year-over-year Received CE Mark approval for commercialization of Eversense 365 in Europe Launched first Eversense 365 AID system integration, with twiist in
- 8mo agoSENSSequel Med Tech and Senseonics Launch Transformative Combination of twiist™ and Eversense® 365GlobeNewswireMANCHESTER, N.H. and GERMANTOWN, Md., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Sequel Med Tech, LLC, a company developing transformative drug delivery technologies, and Senseonics Holdings, Inc. (NASDAQ:SENS), a medical
- 9mo agoSENSSenseonics Receives European Approval for Eversense 365, World's Longest-lasting Continuous Glucose MonitorGlobeNewswireGERMANTOWN, Md., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ:SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose
- 9mo agoSENSSenseonics Holdings, Inc. to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools ConferenceGlobeNewswireGERMANTOWN, Md., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ:SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose
- 10mo agoSENSSenseonics Announces Preliminary Unaudited Revenue for Fourth Quarter 2025 and Provides Business UpdateGlobeNewswirePreliminary unaudited revenue expected to be approximately $14.2 million for Q4 2025, an increase of 71% year-over-year Introduced 2026 revenue guidance of $58-$62 million Expects to report fourth quarter and full year
- 10mo agoSENSSenseonics Announces First Commercial Patients Using Eversense 365 Continuous Glucose Monitor (CGM) with twiist™ Automated Insulin Delivery (AID) SystemGlobeNewswireGERMANTOWN, Md., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ:SENS), a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable CGM
- 11mo agoAZNSENSVTGNVistagen Appoints Nick Tressler as Chief Financial OfficerBusiness WireVistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called
- 1y agoSENSSenseonics Holdings, Inc. to Participate in the Stifel 2025 Healthcare ConferenceGlobeNewswireGERMANTOWN, Md., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE:SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose
- 1y agoSENSSenseonics Announces Transfer to Nasdaq Stock ExchangeGlobeNewswireGERMANTOWN, Md., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE:SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring
- 1y agoSENSSenseonics Holdings, Inc. Reports Third Quarter Financial ResultsGlobeNewswireGenerated Q3 revenue of $8.1 million, representing year-over-year growth of 90% Achieved a 160% increase in U.S. new patient starts over prior year Planning for the transition of CGM commercial responsibility from
- 1y agoSENSSenseonics Holdings, Inc. Schedules Third Quarter 2025 Earnings Release and Conference Call for November 5, 2025 at 4:30 P.M. Eastern TimeGlobeNewswireGERMANTOWN, Md., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE:SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose
- 1y agoSENSSenseonics Announces Preliminary Unaudited Revenue for Third Quarter 2025 and Provides Business UpdateGlobeNewswirePreliminary unaudited revenue of $8.1 million for Q3 2025 Generated record quarterly new patient starts in Q3 2025 Established reverse stock split ratio of 1:20, anticipated to be effective October 17, 2025
- 1y agoSENSSenseonics Holdings, Inc. (SENS) Eversense 365 Commercial Update Call (Transcript)Earnings Call Transcripts
- 1y agoSENSTYO:6523Ascensia Diabetes Care Signs MOU to Transfer Eversense® CGM Distribution to Strategic Partner SenseonicsBusiness Wire- Agreement with Senseonics to transfer commercial activities would integrate Eversense manufacturing and distribution to accelerate growth PHC Holdings Corporation (President, Representative Director and CEO: Kyoko
- 1y agoHTGCSENSSenseonics Signs Memorandum of Understanding with Ascensia Diabetes Care to Take Over Commercialization and Distribution of Eversense 365GlobeNewswireCGM commercial operations to transition from Ascensia Diabetes Care to Senseonics Brian Hansen to be appointed Chief Commercial Officer Non-dilutive debt facility expanded up to $100 million with Hercules Capital to
- 1y agoSENSSenseonics Holdings, Inc. (SENS) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoSENSSenseonics Holdings, Inc. Reports Second Quarter Financial ResultsGlobeNewswireGenerated Q2 revenue of $6.6 million, representing year-over-year growth of 37% Achieved a 79% increase in U.S. new patient starts over prior year GERMANTOWN, Md., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Senseonics
- 1y agoSENSSenseonics Holdings, Inc. Schedules Second Quarter 2025 Earnings Release and Conference Call for August 6, 2025 at 4:30 P.M. Eastern TimeGlobeNewswireGERMANTOWN, Md., July 16, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE:SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose
- 1y agoSENSSenseonics Holdings, Inc. to Host In-Person and Virtual Analyst Event at ADA 2025: Eversense® 365 Continuous Glucose Monitoring System for People with DiabetesGlobeNewswireGERMANTOWN, Md., June 04, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE:SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose
- 1y agoSENSSenseonics Holdings, Inc. Announces Closing of Public Offering, Including Exercise in Full of the Underwriters' Option to Purchase Additional Shares, and Closing of Private PlacementGlobeNewswirePublic offering results in gross proceeds of $57.5 millionPrivate placement results in gross proceeds of approximately $20.3 million GERMANTOWN, Md., May 21, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings,
- 1y agoSENSSenseonics Announces Pricing of $50 Million Public Offering of Common Stock and Concurrent Private PlacementGlobeNewswireGERMANTOWN, Md., May 15, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE:SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring
- 1y agoSENSSenseonics Announces Commencement of $50 Million Public Offering of Common Stock and Concurrent Private PlacementGlobeNewswireGERMANTOWN, Md., May 15, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE:SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring
- 1y agoSENSSenseonics Holdings, Inc. Reports First Quarter Financial ResultsGlobeNewswireQ1 Revenue of $6.3 million, growth year over year of 24% Partnership with Sequel integrates twiist™ automated insulin delivery (AID) system with Eversense® 365 one-year continuous glucose monitor (CGM);
- 1y agoSENSSenseonics Holdings, Inc. Schedules First Quarter 2025 Earnings Release and Conference Call for May 8, 2025 at 4:30 P.M. Eastern TimeGlobeNewswireGERMANTOWN, Md., April 29, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE:SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose
- 1y agoSENSSequel Med Tech and Senseonics Integrate Technologies to Create First Automated Insulin Delivery (AID) System with One-Year Continuous Glucose Monitor (CGM)GlobeNewswiretwiist™ expands compatibility offerings to become the first AID system compatible with Senseonics Eversense® 365 one-year CGM system twiist with Eversense 365 launch expected in Q3 MANCHESTER, N.H. and